中枢神经系统肿瘤样脱髓鞘病变的研究进展
Research Progress on Tumefactive Demyelinating Lesions of Central Nervous System
DOI: 10.12677/acm.2025.153641, PDF,   
作者: 魏 萌, 李秀娟*：重庆医科大学附属儿童医院神经内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童神经发育与认知障碍重庆市重点实验室，重庆
关键词: 瘤样脱髓鞘；临床特征；磁共振成像；治疗；Tumefactive Demyelination； Clinical Characteristics； MRI； Therapy
摘要: 瘤样脱髓鞘病变(Tumefactive demyelinating lesions, TDLs)是一种罕见的由免疫介导的中枢神经系统炎性脱髓鞘疾病，病因及发病机制尚不明确，临床表现多样，主要为运动、认知、感觉障碍等，不具有特异性，对免疫治疗有效。但因其影像学具有水肿及占位效应，常被误诊为中枢神经系统肿瘤或占位性病变，部分病人甚至错误地进行手术治疗，给病人造成损伤。目前诊断的金标准仍为脑活检，但此技术的开展有局限性，因此对于该疾病的识别与诊治仍有一定的挑战。本文对TDLs的临床表现、最新影像学技术、治疗及预后等研究进展进行综述。
Abstract: Tumefactive demyelinating lesions (TDLs) are a rare, immune-mediated inflammatory disorder of the central nervous system (CNS). Etiology and pathogenesis remain largely unknown. Clinical manifestations are heterogeneous, primarily encompassing motor, cognitive, and sensory disturbances, which lack specificity but respond effectively to immunotherapy. However, due to its characteristic edema and mass effect on imaging, TDLs are frequently misdiagnosed as CNS tumors or space-occupying lesions, leading some patients to undergo unnecessary surgical interventions, thereby causing potential harm. Currently, brain biopsy remains the gold standard for diagnosis, however, this technique has inherent limitations, posing challenges for accurate identification and diagnosis of TDLs. This review aims to summarize the clinical features, latest imaging modalities, therapeutic approaches, and prognosis of TDLs.
文章引用：魏萌, 李秀娟. 中枢神经系统肿瘤样脱髓鞘病变的研究进展[J]. 临床医学进展, 2025, 15(3): 498-506. https://doi.org/10.12677/acm.2025.153641

参考文献

[1] van der Velden, M., Bots, G.T. and Endtz, L.J. (1979) Cranial CT in Multiple Sclerosis Showing a Mass Effect. Surgical Neurology, 12, 307-310.
[2] Dagher, A.P. and Smirniotopoulos, J. (1996) Tumefactive Demyelinating Lesions. Neuroradiology, 38, 560-565. [Google Scholar] [CrossRef] [PubMed]
[3] Lucchinetti, C.F., Gavrilova, R.H., Metz, I., Parisi, J.E., Scheithauer, B.W., Weigand, S., et al. (2008) Clinical and Radiographic Spectrum of Pathologically Confirmed Tumefactive Multiple Sclerosis. Brain, 131, 1759-1775. [Google Scholar] [CrossRef] [PubMed]
[4] Nakayama, M., Naganawa, S., Ouyang, M., Jones, K.A., Kim, J., Capizzano, A.A., et al. (2021) A Review of Clinical and Imaging Findings in Tumefactive Demyelination. American Journal of Roentgenology, 217, 186-197. [Google Scholar] [CrossRef] [PubMed]
[5] Vakrakou, A.G., Brinia, M., Svolaki, I., Argyrakos, T., Stefanis, L. and Kilidireas, C. (2022) Immunopathology of Tumefactive Demyelinating Lesions—From Idiopathic to Drug-Related Cases. Frontiers in Neurology, 13, Article 868525. [Google Scholar] [CrossRef] [PubMed]
[6] Katsuse, K., Kurihara, M., Sugiyama, Y., Kodama, S., Takahashi, M., Momose, T., et al. (2019) Aphasic Status Epilepticus Preceding Tumefactive Left Hemisphere Lesion in Anti-Mog Antibody Associated Disease. Multiple Sclerosis and Related Disorders, 27, 91-94. [Google Scholar] [CrossRef] [PubMed]
[7] Shu, Y.Q., Long, Y.M., Wang, S.S., et al. (2019) Brain Histopathological Study and Prognosis in MOG Antibody-Associated Demyelinating Pseudotumor. Annals of Clinical and Translational Neurology, 6, 392-396.
https://pubmed.ncbi.nlm.nih.gov/30847372/
[8] Paty, D.W., Oger, J.J.F., Kastrukoff, L.F., Hashimoto, S.A., Hooge, J.P., Eisen, A.A., et al. (1988) MRI in the Diagnosis of MS. Neurology, 38, 180-185. [Google Scholar] [CrossRef] [PubMed]
[9] Poser, S., Lüer, W., Bruhn, H., Frahm, J., Brück, Y. and Felgenhauer, K. (1992) Acute Demyelinating Disease. Classification and Non-Invasive Diagnosis. Acta Neurologica Scandinavica, 86, 579-585. [Google Scholar] [CrossRef] [PubMed]
[10] Fereidan-Esfahani, M., Decker, P.A., Eckel Passow, J.E., Lucchinetti, C.F., Flanagan, E.P. and Tobin, W.O. (2021) Population-Based Incidence and Clinico-Radiological Characteristics of Tumefactive Demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 29, 782-789. [Google Scholar] [CrossRef] [PubMed]
[11] Cacciaguerra, L., Morris, P., Tobin, W.O., Chen, J.J., Banks, S.A., Elsbernd, P., et al. (2023) Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. Neurology, 100, e1418-e1432. [Google Scholar] [CrossRef] [PubMed]
[12] Vakrakou, A.G., Tzanetakos, D., Evangelopoulos, M., Argyrakos, T., Tzartos, J.S., Anagnostouli, M., et al. (2021) Clinico-Radiologic Features and Therapeutic Strategies in Tumefactive Demyelination: A Retrospective Analysis of 50 Consecutive Cases. Therapeutic Advances in Neurological Disorders, 14, Article 17562864211006503. [Google Scholar] [CrossRef] [PubMed]
[13] Fereidan-Esfahani, M., Decker, P.A., Weigand, S.D., Lopez Chiriboga, A.S., Flanagan, E.P., Tillema, J., et al. (2023) Defining the Natural History of Tumefactive Demyelination: A Retrospective Cohort of 257 Patients. Annals of Clinical and Translational Neurology, 10, 1544-1555. [Google Scholar] [CrossRef] [PubMed]
[14] 王起, 戚晓昆, 刘建国, 等. 脱髓鞘假瘤35例的临床表现和影像及病理特点[J]. 中华神经科杂志, 2007, 40(7): 456-459.
[15] Pérez, C.A., Patnaik, A., Oommen, S., Redko, A. and Mathis, S.B. (2020) Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature. Journal of Child Neurology, 35, 690-699. [Google Scholar] [CrossRef] [PubMed]
[16] Yiu, E.M., Laughlin, S., Verhey, L.H. and Banwell, B.L. (2013) Clinical and Magnetic Resonance Imaging (MRI) Distinctions between Tumefactive Demyelination and Brain Tumors in Children. Journal of Child Neurology, 29, 654-665. [Google Scholar] [CrossRef] [PubMed]
[17] Pittock, S.J. (2005) Clinical Course, Pathological Correlations, and Outcome of Biopsy Proved Inflammatory Demyelinating Disease. Journal of Neurology, Neurosurgery & Psychiatry, 76, 1693-1697. [Google Scholar] [CrossRef] [PubMed]
[18] Kalinowska-Lyszczarz, A., Tillema, J., Tobin, W.O., Guo, Y., Fitz-Gibbon, P.D., Weigand, S.D., et al. (2021) Long-Term Clinical, MRI, and Cognitive Follow-Up in a Large Cohort of Pathologically Confirmed, Predominantly Tumefactive Multiple Sclerosis. Multiple Sclerosis Journal, 28, 441-452. [Google Scholar] [CrossRef] [PubMed]
[19] Hunter, S.F. (2016) Overview and Diagnosis of Multiple Sclerosis. The American Journal of Managed Care, 22, S141-S150.
[20] Faguy, K. (2016) Multiple Sclerosis: An Update. Radiologic Technology, 87, 529-550.
[21] Lacour, A., de Seze, J., Revenco, E., Lebrun, C., Masmoudi, K., Vidry, E., et al. (2004) Acute Aphasia in Multiple Sclerosis. Neurology, 62, 974-977. [Google Scholar] [CrossRef] [PubMed]
[22] Sun, C., Han, J., Lin, Y., Qi, X., Li, C., Liu, J., et al. (2022) Neuroimaging and Clinicopathological Differences between Tumefactive Demyelinating Lesions and Sentinel Lesions of Primary Central Nervous System Lymphoma. Frontiers in Immunology, 13, Article 986473. [Google Scholar] [CrossRef] [PubMed]
[23] 马林, 蔡幼铨, 高元桂, 等. 中枢神经系统脱髓鞘性假瘤的MRI表现[J]. 中华放射学杂志, 2002(7): 25-28.
[24] 张文洛, 戚晓昆, 刘建国, 等. 瘤样炎性脱髓鞘病的影像学特点观察[J]. 中华神经外科杂志, 2007, 23(9): 696-699.
[25] Seewann, A., Enzinger, C., Filippi, M., Barkhof, F., Rovira, A., Gass, A., et al. (2007) MRI Characteristics of Atypical Idiopathic Inflammatory Demyelinating Lesions of the Brain. Journal of Neurology, 255, 1-10. [Google Scholar] [CrossRef] [PubMed]
[26] de Medeiros, F.C., de Albuquerque, L.A.F., Pittella, J.E.H., de Souza, R.B., Gomes Neto, A.P. and Christo, P.P. (2014) Open-ring Enhancement in Pseudotumoral Multiple Sclerosis: Important Radiological Aspect. Case Reports in Neurological Medicine, 2014, 1-5. [Google Scholar] [CrossRef] [PubMed]
[27] 付峰, 陈振东, 董海波, 等. 脑内脱髓鞘假瘤MRI及病理学特征[J]. 中国临床医学影像杂志, 2011, 22(12): 871-873.
[28] Kim, D.S., Na, D.G., Kim, K.H., Kim, J., Kim, E., Yun, B.L., et al. (2009) Distinguishing Tumefactive Demyelinating Lesions from Glioma or Central Nervous System Lymphoma: Added Value of Unenhanced CT Compared with Conventional Contrast-Enhanced MR Imaging. Radiology, 251, 467-475. [Google Scholar] [CrossRef] [PubMed]
[29] Hardy, T.A., Tobin, W.O. and Lucchinetti, C.F. (2016) Exploring the Overlap between Multiple Sclerosis, Tumefactive Demyelination and Baló’s Concentric Sclerosis. Multiple Sclerosis Journal, 22, 986-992. [Google Scholar] [CrossRef] [PubMed]
[30] Mabray, M.C., Cohen, B.A., Villanueva-Meyer, J.E., Valles, F.E., Barajas, R.F., Rubenstein, J.L., et al. (2015) Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions from Primary Brain Neoplasms. American Journal of Roentgenology, 205, 1075-1085. [Google Scholar] [CrossRef] [PubMed]
[31] Malhotra, H., Jain, K., Agarwal, A., Singh, M., Yadav, S., Husain, M., et al. (2008) Characterization of Tumefactive Demyelinating Lesions Using MR Imaging and In-Vivo Proton MR Spectroscopy. Multiple Sclerosis Journal, 15, 193-203. [Google Scholar] [CrossRef] [PubMed]
[32] Kalis, M., Bowen, B.C. and Quencer, R.M. (2007) Metabolite Findings in Tumefactive Demyelinating Lesions Utilizing Short Echo Time Proton Magnetic Resonance Spectroscopy. American Journal of Neuroradiology, 28, 1427-1427. [Google Scholar] [CrossRef] [PubMed]
[33] 石洋洋, 李春花, 李辉, 等. 1H-MRS对颅内淋巴瘤与肿瘤样脱髓鞘病变的鉴别诊断价值[J]. 中国医学影像学杂志, 2015, 23(4): 245-249+259.
[34] Lu, S.S., Kim, S.J., Kim, H.S., Choi, C.G., Lim, Y.M., Kim, E.J., et al. (2013) Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions. American Journal of Neuroradiology, 35, 270-277. [Google Scholar] [CrossRef] [PubMed]
[35] Ikeguchi, R., Shimizu, Y., Abe, K., Shimizu, S., Maruyama, T., Nitta, M., et al. (2018) Proton Magnetic Resonance Spectroscopy Differentiates Tumefactive Demyelinating Lesions from Gliomas. Multiple Sclerosis and Related Disorders, 26, 77-84. [Google Scholar] [CrossRef] [PubMed]
[36] 李咏梅, 谢鹏, 吕发金, 等. 动态磁敏感增强灌注成像对假瘤样脱髓鞘病的诊断价值[J]. 第三军医大学学报, 2008(14): 1367-1370.
[37] Frederick, M.C. and Cameron, M.H. (2016) Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders. Current Neurology and Neuroscience Reports, 16, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[38] Kuhle, J., Disanto, G., Dobson, R., Adiutori, R., Bianchi, L., Topping, J., et al. (2015) Conversion from Clinically Isolated Syndrome to Multiple Sclerosis: A Large Multicentre Study. Multiple Sclerosis Journal, 21, 1013-1024. [Google Scholar] [CrossRef] [PubMed]
[39] Tremblay, M.A., Villanueva-Meyer, J.E., Cha, S., Tihan, T. and Gelfand, J.M. (2017) Clinical and Imaging Correlation in Patients with Pathologically Confirmed Tumefactive Demyelinating Lesions. Journal of the Neurological Sciences, 381, 83-87. [Google Scholar] [CrossRef] [PubMed]
[40] Jeong, I.H., Kim, S., Hyun, J., Joung, A., Cho, H. and Kim, H.J. (2015) Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-Up Observations. Journal of the Neurological Sciences, 358, 118-124. [Google Scholar] [CrossRef] [PubMed]
[41] 黄鑫, 戚晓昆, 刘建国, 等. 经病理证实的以瘤样脱髓鞘病为首发表现的多发性硬化临床分析[J]. 中国神经免疫学和神经病学杂志, 2016, 23(2): 83-88.
[42] Hu, W. and Lucchinetti, C.F. (2009) The Pathological Spectrum of CNS Inflammatory Demyelinating Diseases. Seminars in Immunopathology, 31, 439-453. [Google Scholar] [CrossRef] [PubMed]
[43] 孙辰婧, 戚晓昆, 刘建国, 等. 颅内肿瘤样脱髓鞘病病理分期特点分析[C]//中华医学会, 中华医学会神经病学分会. 中华医学会第十八次全国神经病学学术会议论文汇编(下). 2015: 315.
[44] Erana-Rojas, I.E., Barboza-Quintana, A., Ayala, A.G. and Fuller, G.N. (2002) Demyelinating Pseudotumor. Annals of Diagnostic Pathology, 6, 265-271. [Google Scholar] [CrossRef] [PubMed]
[45] Chen, X., Chen, Y., Fang, W., Wu, Z., Wang, D., Xu, Y., et al. (2022) Integrative and Comparative Single-Cell Analysis Reveals Transcriptomic Difference between Human Tumefactive Demyelinating Lesion and Glioma. Communications Biology, 5, Article No. 941. [Google Scholar] [CrossRef] [PubMed]
[46] Morin, M., Patenaude, Y., Sinsky, A.B., Banwell, B. and Sébire, G. (2011) Solitary Tumefactive Demyelinating Lesions in Children. Journal of Child Neurology, 26, 995-999. [Google Scholar] [CrossRef] [PubMed]
[47] Altintas, A., Petek, B., Isik, N., Terzi, M., Bolukbasi, F., Tavsanli, M., et al. (2012) Clinical and Radiological Characteristics of Tumefactive Demyelinating Lesions: Follow-Up Study. Multiple Sclerosis Journal, 18, 1448-1453. [Google Scholar] [CrossRef] [PubMed]
[48] 张文洛, 戚晓昆. 大剂量甲泼尼龙冲击联合丙种球蛋白治疗重症脱髓鞘脑病2例[J]. 海军总医院学报, 2007(1): 60-61.
[49] Weinshenker, B.G., O’Brien, P.C., Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F., Dodick, D.W., et al. (1999) A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease. Annals of Neurology, 46, 878-886. [Google Scholar] [CrossRef] 
[50] Mao-Draayer, Y., Braff, S., Pendlebury, W. and Panitch, H. (2002) Treatment of Steroid-Unresponsive Tumefactive Demyelinating Disease with Plasma Exchange. Neurology, 59, 1074-1077. [Google Scholar] [CrossRef] [PubMed]
[51] Fan, X., Mahta, A., De Jager, P.L. and Kesari, S. (2012) Rituximab for Tumefactive Inflammatory Demyelination: A Case Report. Clinical Neurology and Neurosurgery, 114, 1326-1328. [Google Scholar] [CrossRef] [PubMed]
[52] Dastgir, J. and DiMario, F.J. (2009) Acute Tumefactive Demyelinating Lesions in a Pediatric Patient with Known Diagnosis of Multiple Sclerosis: Review of the Literature and Treatment Proposal. Journal of Child Neurology, 24, 431-437. [Google Scholar] [CrossRef] [PubMed]
[53] Hardy, T.A. and Chataway, J. (2013) Tumefactive Demyelination: An Approach to Diagnosis and Management. Journal of Neurology, Neurosurgery & Psychiatry, 84, 1047-1053. [Google Scholar] [CrossRef] [PubMed]
[54] Visser, F., Wattjes, M.P., Pouwels, P.J.W., Linssen, W.H.J.P. and van Oosten, B.W. (2012) Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment. Neurology, 79, 2000-2003. [Google Scholar] [CrossRef] [PubMed]
[55] Jeung, L., Smits, L.M.G., Hoogervorst, E.L.J., van Oosten, B.W. and Frequin, S.T.F.M. (2020) A Tumefactive Demyelinating Lesion in a Person with MS after Five Years of Fingolimod. Multiple Sclerosis and Related Disorders, 40, Article 101978. [Google Scholar] [CrossRef] [PubMed]
[56] Algahtani, H., Shirah, B. and Alassiri, A. (2017) Tumefactive Demyelinating Lesions: A Comprehensive Review. Multiple Sclerosis and Related Disorders, 14, 72-79. [Google Scholar] [CrossRef] [PubMed]
[57] Balloy, G., Pelletier, J., Suchet, L., Lebrun, C., Cohen, M., Vermersch, P., et al. (2018) Inaugural Tumor-Like Multiple Sclerosis: Clinical Presentation and Medium-Term Outcome in 87 Patients. Journal of Neurology, 265, 2251-2259. [Google Scholar] [CrossRef] [PubMed]
[58] Li, X., Miao, X., Wang, Y., Sun, J., Gao, H., Han, J., et al. (2022) Central Nervous System Tumefactive Demyelinating Lesions: Risk Factors of Relapse and Follow-Up Observations. Frontiers in Immunology, 13, Article 1052678. [Google Scholar] [CrossRef] [PubMed]

为你推荐